Gattex (teduglutide) / Takeda - LARVOL DELTA

Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study. (PubMed, Pediatr Res) - P | "The GLP-2 analog medication teduglutide was approved by the FDA in 2019 for children receiving parenteral support for intestinal failure. We enrolled 140 such children to evaluate its safety and effectiveness profile in a post-marketing study. Substantial reductions in parenteral calories and volume were noted with a reasonable safety profile. Some reductions in nutritional status (weight and BMI but not height) were also noted. Careful monitoring of nutritional status while on this new medication is warranted."

Journal • P4 data • Gastrointestinal Disorder • Short Bowel Syndrome

TAK-633-3009: A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome (clinicaltrials.gov) - P3 | N=13 | Active, not recruiting | Sponsor: Takeda | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Disorder • Short Bowel Syndrome

Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review. (PubMed, Int J Surg Case Rep) - "Body weight stabilized, CRBSI resolved, and disease-specific QoL improved markedly. Even in ultra-short-bowel SBS-IF, teduglutide may achieve PN independence and clinically meaningful improvements in gastrointestinal symptoms, weight maintenance, and QoL."

Journal • CNS Disorders • Gastrointestinal Disorder • Infectious Disease • Short Bowel Syndrome • Sleep Disorder

Comment on "Real-World Experience of Teduglutide for the Treatment of Short Bowel Syndrome-Associated Intestinal Failure". (PubMed, Clin Nutr ESPEN) - No abstract available

Journal • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

Five-Year Safety Outcomes of Teduglutide in Adults With Short Bowel Syndrome-Associated Intestinal Failure: A Propensity Score-Matched Analysis (ACG 2026) - "One-to-one PSM was performed on demographics (age, sex, race), SBS etiology (Crohn's disease, mesenteric ischemia, volvulus, GI malignancy), comorbidity burden, medications (proton pump inhibitors, loperamide, octreotide, opioids), procedures, and baseline laboratory values (albumin, creatinine, eGFR, ALT, AST, total bilirubin). Before matching, 739 teduglutide-treated and 23,184 control patients were identified. After 1:1 PSM, 706 well-balanced patients remained per cohort (all SMDs < 0.10). Mean follow-up was 1,047 vs."

Clinical • Acute Kidney Injury • Biliary Cancer • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Bowel Disease • Nephrology • Orthopedics • Pancreatitis • Renal Disease • Short Bowel Syndrome • Venous Thromboembolism

A Marked Response to GLP-1 Receptor Agonist Therapy in Refractory High-Output Jejunostomy (ACG 2026) - "Despite loperamide, PPIs, octreotide, and PN, stoma output remained uncontrolled...Unlike teduglutide, often limited by cost and availability, liraglutide may represent a useful adjunctive strategy targeting dysmotility and hypersecretion...This case highlights potential utility of GLP-1 receptor agonists in chemoradiotherapy-related adhesive enteropathy complicated by severe high-output jejunostomy. Figure: Erect abdominal radiograph demonstrating dilated proximal small bowel loops consistent with high-grade obstruction Figure: Intraoperative view showing densely matted small bowel loops and extensive post-treatment adhesions"

Gastrointestinal Disorder • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE AND PREDICTORS OF LONG-TERM PARENTERAL NUTRITION REQUIREMENTS IN ADULTS WITH SHORT BOWEL SYNDROME AND INTESTINAL FAILURE: INTERIM ANALYSIS OF THE SBS REGISTRY (UEGW 2026) - No abstract available

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

TEDUGLUTIDE ENHANCES INTESTINAL ABSORPTION IN SHORT BOWEL SYNDROME BUT IS ASSOCIATED WITH LOWER ORAL CALORIC INTAKE OVER TIME (UEGW 2026) - No abstract available

Gastrointestinal Disorder • Short Bowel Syndrome

IMPACT OF TEDUGLUTIDE ON PARENTERAL NUTRITION VOLUME AND PATIENT-PERCEIVED HEALTH IN THE BELGIAN SHORT BOWEL SYNDROME POPULATION (UEGW 2026) - No abstract available

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

GASTROINTESTINAL SAFETY OF TEDUGLUTIDE IN SHORT BOWEL SYNDROME: A PROPENSITY-MATCHED REAL-WORLD ANALYSIS STRATIFIED BY TREATMENT DURATION (UEGW 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

SUCCESSFUL USE OF COMBINED TEDUGLUTIDE AND USTEKINUMAB IN CROHN'S DISEASE–RELATED SHORT BOWEL SYNDROME: A CASE REPORT (UEGW 2026) - No abstract available

Case report • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

MULTIFOCAL SMALL-BOWEL ADENOMAS DURING TEDUGLUTIDE THERAPY IN TYPE II SHORT BOWEL SYNDROME: THE NEED FOR A PAN-ENTERIC SURVEILLANCE (UEGW 2026) - No abstract available

Gastrointestinal Disorder • Short Bowel Syndrome

Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review. (PubMed, Pediatr Surg Int) - "Teduglutide was generally well tolerated. Although further long-term data are needed, current evidence supports teduglutide's role as an effective adjunct in the management of SBS in children."

Journal • Review • Gastrointestinal Disorder • Hepatology • Pediatrics • Short Bowel Syndrome

Weaning infants with short bowel syndrome associated intestinal failure from parenteral nutrition: An ERNICA multicentre survey. (PubMed, Intest Fail) - "Details regarding oral/nasogastric (NG) feeding when weaning PN, use of protocols/guidelines, criteria for PN cycling/reducing infusion hours, dietary recommendations, use of synthetic glucagon-like peptide-2 (teduglutide), antibiotics for intestinal bacterial overgrowth and long-term follow-up practices were requested in children with neonatal onset SBS-IF...NG-tube feeding was used alongside oral intake in most centres, but other practices differed widely. Multicentre studies investigating which practices are associated with the best outcome for infants with SBS-IF are needed to develop evidence-based guidelines."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome

Optimizing teduglutide treatment regimens in children with short bowel syndrome. (PubMed, Front Pediatr) - "Determining the optimal timing to initiate TED for children with SBS requires individualized strategies rather than a universal recommendation. In addition, long-term administration of TED(at least one year before reassessing treatment response) is required in the treatment of SBS-IF to achieve the best therapeutic effect, which is essential for optimizing TED treatment regimens in children."

Journal • Review • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

A Study of Teduglutide in Japanese People With Short Bowel Syndrome (clinicaltrials.gov) - P=N/A | N=250 | Completed | Sponsor: Takeda | Active, not recruiting ➔ Completed

Trial completion • Gastrointestinal Disorder • Short Bowel Syndrome

Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment. (PubMed, BMC Pediatr) - "Teduglutide significantly enhances HRQoL in children with SBS and their caregivers, potentially through intestinal rehabilitation and reduced PN dependence."

HEOR • Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry. (PubMed, Talanta) - "The development of Teduglutide purity CRM (GBW09342) enables the establishment of accurate and reliable analytical methods for purity assessment, which is essential for ensuring the quality, consistency, and clinical safety of corresponding pharmaceutical products. It also provides a reliable reference for the quality control of other peptide-related drugs."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome

CALCIUM-SENSING RECEPTOR ACTIVATION TO REDUCE DUMPING AND IMPROVE FEEDING: A PILOT STUDY OF CACO₃ THERAPY IN CHILDREN WITH SHORT BOWEL SYNDROME (ESPGHAN 2026) - "Two of three patients dependent on parenteral support for 3–6 years were fully weaned within 6–8 weeks, avoiding planned Gattex therapy or transplant referral...Randomized controlled trials are warranted. Contact e-mail address [email protected]"

Clinical • Constipation • Endocrine Disorders • Gastrointestinal Disorder • Inflammation • Metabolic Disorders • Short Bowel Syndrome

LONG-TERM EVALUATION OF GLUCAGON-LIKE PEPTIDE-2, GLP-2 TREATMENT IN CHILDREN WITH SHORT BOWEL SYNDROME–ASSOCIATED INTESTINAL FAILURE (SBS-IF): 7-10 YEARS FOLLOW-UP (ESPGHAN 2026) - "Teduglutide, a glucagon-like peptide-2(GLP-2) analogue, promotes intestinal adaptation and can reduce PN dependency...No longterm adverse were detected.Continuous nutritional and clinical monitoring remains essential. Contact e-mail address [email protected]"

Clinical • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Short Bowel Syndrome • Thrombosis

NOVEL PERCC1 VARIANT AND ENTEROENDOCRINE HORMONE DEFICIENCY IN A PATIENT WITH PERCC1 ASSOCIATED ENTEROPATHY: NEW DIAGNOSTIC AND THERAPEUTIC INSIGHTS (ESPGHAN 2026) - "Early recognition is essential, as timely diagnosis may enable targeted GLP-2 analogue (Teduglutide) therapy...The case illustrates precision child health, where identifying a rare but actionable condition enabled targeted therapy with GLP-2 analogue. Contact e-mail address [email protected]"

Clinical • GAST • SYP

ASSESSING THE HEALTH-RELATED QUALITY OF LIFE AND CLINICAL EFFECT IN CHILDREN WITH SHORT BOWEL SYNDROME RECEIVING TEDUGLUTIDE TREATMENT (ESPGHAN 2026) - "Conclusions Teduglutide significantly enhances HRQoL of children with SBS and their caregivers, potentially through intestinal rehabilitation and reduced PN dependency. Contact e-mail address [email protected]"

Clinical • HEOR • Gastrointestinal Disorder • Short Bowel Syndrome

PROSPECTIVE COURSE OF MORE THAN ONE HUNDRED EUROPEAN CHILDREN WITH SHORT BOWEL SYNDROME TREATED WITH TEDUGLUTIDE FOR 2 YEARS (ESPGHAN 2026) - "These findings support the long-term effectiveness of teduglutide as an individualized treatment strategy in paediatric intestinal failure. Contact e-mail address [email protected]"

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

Association between teduglutide treatment and long-term reductions in parenteral support: an observational cohort study of adults with short bowel syndrome. (PubMed, Clin Nutr ESPEN) - "In real-world practice, teduglutide treatment was associated with lower parenteral support volumes in adult patients with SBS-IF, with 26.9% of patients achieving independence from parenteral support. No adverse events outside the known safety profile of teduglutide were identified, and findings were consistent with previously reported clinical trial and real-world studies."

Journal • Observational data • Crohn's disease • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience. (PubMed, Intest Fail) - "Teduglutide reduced PN dependence in children with SBS-IF, with over half achieving enteral autonomy. These findings support its role in intestinal rehabilitation and emphasize the need for individualized treatment strategies based on baseline clinical characteristics associated with response."

Clinical data • Journal • Gastrointestinal Disorder • Hepatology • Infectious Disease • Pediatrics • Septic Shock • Short Bowel Syndrome